- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04955171
BEOVU Versus Eylea in the Treatment of Diabetic Macular Edema
July 4, 2021 updated by: Tarek Roshdy mohamed Mahgoub ELhamaky, Benha University
Outcome of Brolucizumab-dbll and Aflibercept Intravitreal Injection in the Treatment of Diabetic Macular Edema
Diabetic macular edema degeneration occur is a vision threatening condition.
The investigators compare the efficacy of BEOVU and Eylea intravitreal treatment in the management
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
Baseline ,and postoperative 1 ,6 and 12 months full ophthalmic examination was done.
Procedure included randomized intravitreal injection of Brolucizumab(BEOVU®, Genentech, South Francisco, CA) and of aflibercept (Eylea;Regeneron, Tarrytown,NY)
Study Type
Interventional
Enrollment (Anticipated)
60
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: TAREK R ELHAMAKY, MD
- Phone Number: +9712 443 8999
- Email: thamaky@ibnnafees.com
Study Contact Backup
- Name: TAREK ELHAMAKY
- Phone Number: +9712 443 8999
- Email: thamaky@ibnnafees.com
Study Locations
-
-
-
Abu Dhabi, United Arab Emirates, 46266
- Recruiting
- INMC
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Diabetic macular edema
Exclusion Criteria:
- other causes of macular edema
- other macular diseases
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: BEOVU
Intravitreal injection of BEOVU 3 loading injections( monthly) then under treat and extent regimen
|
BEOVU intravitreal injection
Other Names:
|
Active Comparator: Eylea
Intravitreal injection of Eylea 3 loading injections( monthly) then under treat and extent regimen
|
BEOVU intravitreal injection
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Best corrected visual acuity (BCVA)
Time Frame: 12 months
|
Change in BCVA in LOG MARS(logarithm minimum angle of resolution
|
12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: tarek elhamaky, MD, benha faculty of medicine
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 12, 2021
Primary Completion (Anticipated)
March 1, 2022
Study Completion (Anticipated)
April 1, 2022
Study Registration Dates
First Submitted
July 4, 2021
First Submitted That Met QC Criteria
July 4, 2021
First Posted (Actual)
July 8, 2021
Study Record Updates
Last Update Posted (Actual)
July 8, 2021
Last Update Submitted That Met QC Criteria
July 4, 2021
Last Verified
July 1, 2021
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Hamaky15
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Yes
IPD Plan Description
by direct contact through email
IPD Sharing Time Frame
UNLIMITED
IPD Sharing Supporting Information Type
- Study Protocol
- Statistical Analysis Plan (SAP)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Macular Edema
-
Federico II UniversityCompletedPseudophakic Cystoid Macular Edema
-
California Retina ConsultantsRegeneron PharmaceuticalsCompletedDiabetic Macular Edema | Cystoid Macular EdemaUnited States
-
Postgraduate Institute of Medical Education and...CompletedDiabetic Macular Edema | Vision Disorders | Macular Edema, Cystoid | Clinically Significant Macular EdemaIndia
-
OcugenNot yet recruitingDiabetic Macular Edema | Center Involved Diabetic Macular Edema
-
Vitreo-Retinal Associates, MichiganVan Andel Research InstituteCompletedDiabetic Macular Edema | Exudative Macular DegenerationUnited States
-
OculisICON plcRecruitingDiabetic Macular EdemaUnited States
-
Novartis PharmaceuticalsNot yet recruiting
-
Hoffmann-La RocheRecruitingUveitic Macular EdemaKorea, Republic of, United Kingdom, China, United States, Netherlands, Canada, Israel, Austria, Brazil, Italy, Taiwan, Poland, Portugal, Mexico
-
Vista KlinikNot yet recruitingDiabetic Macular Edema
-
Chinese University of Hong KongRecruiting
Clinical Trials on BEOVU intravitreal injection
-
Benha UniversityRecruitingMacula Lutea DegenerationUnited Arab Emirates
-
Vista KlinikNovartisTerminatedNeovascular Age-related Macular DegenerationSwitzerland
-
Yeungnam University College of MedicineNovartisNot yet recruitingAge-Related Macular Degeneration | Pachychoroid Neovasculopathy
-
Jeffrey S HeierKato Pharmaceuticals, Inc.CompletedVitreomacular Traction | Vitreomacular Adhesion | Vitreomacular AttachmentUnited States
-
Indonesia UniversityBayerCompletedDiabetic Retinopathy | Diabetic Macular Edema | Clinically Significant Macular EdemaIndonesia
-
Second Affiliated Hospital of Xi'an Jiaotong UniversityCompletedNeovascular GlaucomaChina
-
Afyonkarahisar Health Sciences UniversityCompleted
-
Hemera BiosciencesWithdrawnGeographic Atrophy | Dry Age-related Macular Degeneration | Gene Therapy | Intravitreal Injection
-
Peregrine Eye and Laser InstituteCompletedDiabetic Macular Edema | Choroidal Neovascularization | Neovascular Age-related Macular Degeneration | Uveitic Macular Edema | Retinal Vein Occlusion With Macular EdemaPhilippines
-
Novartis PharmaceuticalsCompletedNeovascular Age-related Macular Degeneration (nAMD)India